Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127.20 EUR | -0.62% | -2.19% | -6.26% |
Sep. 09 | BEIERSDORF AG : Gets a Neutral rating from Bernstein | ZD |
Sep. 04 | Beiersdorf: partnership with American Macro Biologics | CF |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 7.65B | 7.02B | 7.63B | 8.8B | 9.45B | |||||
Total Revenues | 7.65B | 7.02B | 7.63B | 8.8B | 9.45B | |||||
Cost of Goods Sold, Total | 3.22B | 2.98B | 3.27B | 3.84B | 4.03B | |||||
Gross Profit | 4.43B | 4.04B | 4.36B | 4.96B | 5.42B | |||||
Selling General & Admin Expenses, Total | 3.1B | 2.89B | 3.13B | 3.53B | 3.83B | |||||
R&D Expenses | 236M | 246M | 268M | 291M | 320M | |||||
Other Operating Expenses | -30M | -7M | -45M | -85M | 80M | |||||
Other Operating Expenses, Total | 3.3B | 3.13B | 3.35B | 3.74B | 4.23B | |||||
Operating Income | 1.13B | 908M | 1.01B | 1.22B | 1.18B | |||||
Interest Expense, Total | -13M | -13M | -14M | -16M | -26M | |||||
Interest And Investment Income | 37M | 33M | 32M | 36M | 43M | |||||
Net Interest Expenses | 24M | 20M | 18M | 20M | 17M | |||||
Currency Exchange Gains (Loss) | -25M | -14M | 5M | -69M | -47M | |||||
Other Non Operating Income (Expenses) | -6M | -18M | -36M | -6M | -5M | |||||
EBT, Excl. Unusual Items | 1.12B | 896M | 993M | 1.16B | 1.15B | |||||
Restructuring Charges | -41M | -48M | -54M | -61M | -31M | |||||
Merger & Related Restructuring Charges | -25M | -14M | -17M | -6M | -7M | |||||
Impairment of Goodwill | - | -10M | -9M | -8M | -5M | |||||
Gain (Loss) On Sale Of Assets | -21M | -3M | 0 | 12M | 7M | |||||
Asset Writedown | - | - | - | - | - | |||||
Other Unusual Items | - | - | -6M | -5M | -8M | |||||
EBT, Incl. Unusual Items | 1.04B | 821M | 907M | 1.1B | 1.1B | |||||
Income Tax Expense | 301M | 244M | 252M | 325M | 356M | |||||
Earnings From Continuing Operations | 736M | 577M | 655M | 771M | 749M | |||||
Net Income to Company | 736M | 577M | 655M | 771M | 749M | |||||
Minority Interest | -18M | -17M | -17M | -16M | -13M | |||||
Net Income - (IS) | 718M | 560M | 638M | 755M | 736M | |||||
Net Income to Common Incl Extra Items | 718M | 560M | 638M | 755M | 736M | |||||
Net Income to Common Excl. Extra Items | 718M | 560M | 638M | 755M | 736M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 3.17 | 2.47 | 2.81 | 3.33 | 3.24 | |||||
Basic EPS - Continuing Operations | 3.17 | 2.47 | 2.81 | 3.33 | 3.24 | |||||
Basic Weighted Average Shares Outstanding | 227M | 227M | 227M | 227M | 227M | |||||
Net EPS - Diluted | 3.17 | 2.47 | 2.81 | 3.33 | 3.24 | |||||
Diluted EPS - Continuing Operations | 3.17 | 2.47 | 2.81 | 3.33 | 3.24 | |||||
Diluted Weighted Average Shares Outstanding | 227M | 227M | 227M | 227M | 227M | |||||
Normalized Basic EPS | 3.02 | 2.39 | 2.66 | 3.14 | 3.11 | |||||
Normalized Diluted EPS | 3.02 | 2.39 | 2.66 | 3.14 | 3.11 | |||||
Dividend Per Share | 0.7 | 0.7 | 0.7 | 0.7 | 1 | |||||
Payout Ratio | 22.14 | 28.39 | 24.92 | 21.06 | 21.6 | |||||
American Depositary Receipts Ratio (ADR) | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.3B | 1.09B | 1.22B | 1.43B | 1.4B | |||||
EBITA | 1.16B | 932M | 1.03B | 1.25B | 1.22B | |||||
EBIT | 1.13B | 908M | 1.01B | 1.22B | 1.18B | |||||
EBITDAR | 1.34B | 1.11B | 1.24B | 1.46B | 1.44B | |||||
Effective Tax Rate - (Ratio) | 29.03 | 29.72 | 27.78 | 29.65 | 32.22 | |||||
Current Domestic Taxes | 101M | 64M | 76M | 65M | 109M | |||||
Current Foreign Taxes | 237M | 191M | 193M | 272M | 307M | |||||
Total Current Taxes | 338M | 255M | 269M | 337M | 416M | |||||
Total Deferred Taxes | -37M | -11M | -17M | -12M | -60M | |||||
Normalized Net Income | 684M | 543M | 604M | 712M | 705M | |||||
Interest on Long-Term Debt | 3M | - | - | - | 6M | |||||
Non-Cash Pension Expense | 14M | 9M | 8M | 18M | 12M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | 1.64B | 1.55B | 1.69B | 1.88B | 2.08B | |||||
Selling and Marketing Expenses | 2.67B | 2.48B | 2.68B | 3B | 3.25B | |||||
General and Administrative Expenses | 416M | 400M | 448M | 524M | 570M | |||||
Research And Development Expense From Footnotes | 236M | 246M | 268M | 291M | 320M | |||||
Net Rental Expense, Total | 35M | 22M | 27M | 34M | 40M | |||||
Imputed Operating Lease Interest Expense | 15.29M | 9.78M | 20.3M | 21.13M | 48.51M | |||||
Imputed Operating Lease Depreciation | 19.71M | 12.22M | 6.7M | 12.87M | -8.51M |